Therapy Areas: Central Nervous System
Algiax Pharmaceuticals Announces First Patient Enrolled in Phase IIa Multi-center Proof-of-Concept Study Evaluating AP-325 in Chronic Neuropathic Pain
21 September 2020 - - The first patient has been enrolled in the "CURE" study, Germany-based biotechnology company Algiax Pharmaceuticals, a clinical-stage biotechnology company focused on development of GABAA receptor modulators for neuropathic pain and other indications with unmet medical need, said.

Top-line Data for the "CURE" Study Anticipated in Fourth Quarter 2021

In times of COVID-19, conducting a clinical trial that does not contribute to fighting the pandemic is doubly difficult.

Nevertheless, Algiax has succeeded in initiating the "CURE" study of its lead candidate AP-325. This brings the company a further step closer to its goal the treatment of chronic neuropathic pain without causing serious side-effects on the central nervous system and thus an important approach in the fight against the opiate crisis.

The CURE study is a randomized, double-blind, placebo controlled, parallel group study to evaluate the efficacy and safety after repeated oral dosing of Algiax´ lead product AP-325.

The subjects had previously been diagnosed with peripheral post-surgical neuropathic pain after breast surgery, chest surgery or groin hernia repair. The aim is to enroll 94 subjects in 13 participating clinical sites in Germany, Spain and the Czech Republic.

Algiax Pharmaceuticals is a clinical-stage biotechnology company established in 2011.

It is dedicated to the discovery and development of innovative products to treat diseases with a high unmet medical need. Algiax' lead candidate AP-325 is in clinical development for the treatment of neuropathic pain.

AP-325 is a small-molecule GABAA receptor modulator in clinical development as a therapy for neuropathic pain.

Apart from AP-325, Algiax has discovered novel GABAA receptor modulator compounds called Thioacrylamide derivatives. The company is advancing a selection of ThAcs derivatives from its discovery to preclinical characterization.

The main focus area for these novel compounds will be the treatment of diabetes.